Skip to main content
. 2021 Jan 29;11(1):e2021155. doi: 10.5826/dpc.1101a155

Figure 3.

Figure 3

(A) A patient with non-small cell lung carcinoma who was treated with a combination of nivolumab and ipilimumab developed palmoplantar pustulosis after the third cycle. (B) Significant improvement of the skin after 2 months of treatment. (C) However, the patient experienced severe psoriatic arthritis and was switched to apremilast.